Gilead Sciences — Biomedical Watch V2

Traitements5programmes

Essais2liés

Publications3liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
DomvanalimabMaster protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (HNSCC) in various substudies. Substudy-01 will evaluate the efficacy and safety of novel combination of treatment regimens, domvanalimab (DOM) and zimberelimab (ZIM) combined with chemotherapy vs ZIM combined with chemotherapy. The primary objective is to assess the efficacy of DOM and ZIM in combination with chemotherapy versus ZIM in combination with chemotherapy.	Cancer	Phase 2	À vérifier	United States, Australia, China, France, Italy, Malaysia, Spain, Taiwan, …	À vérifier
Sacituzumab govitecan-hziyThe goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).	Cancer	Phase 3	Ralentissement de la progression	United States, Australia, Brazil, Canada, China, Czechia, France, Germany, …	À vérifier
ZimberelimabMaster protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (HNSCC) in various substudies. Substudy-01 will evaluate the efficacy and safety of novel combination of treatment regimens, domvanalimab (DOM) and zimberelimab (ZIM) combined with chemotherapy vs ZIM combined with chemotherapy. The primary objective is to assess the efficacy of DOM and ZIM in combination with chemotherapy versus ZIM in combination with chemotherapy.	Cancer	Phase 2	À vérifier	United States, Australia, China, France, Italy, Malaysia, Spain, Taiwan, …	À vérifier
Sacituzumab govitecan-hziyThe goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).	Cancer	Phase 3	Ralentissement de la progression	United States, Australia, Brazil, Canada, China, Czechia, France, Germany, Greece, Hong Kong, Israel, Italy, Japan, Poland, Singapore, South Korea, Spain, Taiwan, United Kingdom	À vérifier
DomvanalimabMaster protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (HNSCC) in various substudies. Substudy-01 will evaluate the efficacy and safety of novel combination of treatment regimens, domvanalimab (DOM) and zimberelimab (ZIM) combined with chemotherapy vs ZIM combined with chemotherapy. The primary objective is to assess the efficacy of DOM and ZIM in combination with chemotherapy versus ZIM in combination with chemotherapy.	Cancer	Phase 2	À vérifier	United States, Australia, China, France, Italy, Malaysia, Spain, Taiwan, United Kingdom	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
Domvanalimab	Cancer	Phase 2	NCT06727565	VELOCITY-HNSCC — Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01	ACTIVE_NOT_RECRUITING
Sacituzumab govitecan-hziy	Cancer	Phase 3	NCT06486441	Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)	ACTIVE_NOT_RECRUITING

Publications

3

Molécule	Indication / population	Titre	Journal	Date
Sacituzumab govitecan-hziy		Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer.	European journal of nuclear medicine and molecular imaging
Sacituzumab govitecan-hziy		Advances in targeted therapy for triple-negative breast cancer: a review of key antigens and recent advances.	Journal of drug targeting
Sacituzumab govitecan-hziy		Sacituzumab-induced severe or febrile neutropenia and G-CSF utilization and cost for advanced HER2-negative breast cancer: a single-center retrospective analysis.	Breast cancer research and treatment